NAGIOS: RODERIC FUNCIONANDO

Increased quality of life in patients with breakthrough cancer pain after individualized therapy : the CAVIDIOM study

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Increased quality of life in patients with breakthrough cancer pain after individualized therapy : the CAVIDIOM study

dc.contributor.author	González Villarroel, Paula
dc.contributor.author	Gumà Padró, Josep
dc.contributor.author	Marquina, Gloria
dc.contributor.author	Martínez Jáñez, Noelia
dc.contributor.author	Esteban González, Emilio
dc.contributor.author	Antón, Antonio
dc.contributor.author	Berzosa Sánchez, Miguel
dc.contributor.author	Rodrigo Cáceres, Alberto
dc.contributor.author	López López, Rafael
dc.contributor.author	Escala Cornejo, Roberto
dc.contributor.author	Borrega García, Pablo
dc.contributor.author	Marse Fabregat, Raquel
dc.contributor.author	Castelo Fernández, Beatriz
dc.contributor.author	López Bermudo, Cristina
dc.contributor.author	Camps Herrero, Carlos
dc.date.accessioned	2023-04-18T16:24:18Z
dc.date.available	2023-04-18T16:24:18Z
dc.date.issued	2022
dc.identifier.citation	González Villarroel, Paula Gumà Padró, Josep Marquina, Gloria Martínez Jáñez, Noelia Esteban González, Emilio Antón, Antonio Berzosa Sánchez, Miguel Rodrigo Cáceres, Alberto López López, Rafael Escala Cornejo, Roberto Borrega García, Pablo Marse Fabregat, Raquel Castelo Fernández, Beatriz López Bermudo, Cristina Camps Herrero, Carlos 2022 Increased quality of life in patients with breakthrough cancer pain after individualized therapy : the CAVIDIOM study Future Oncology 18 35 3913 3927
dc.identifier.uri	https://hdl.handle.net/10550/86095
dc.description.abstract	Aim: To evaluate the quality of life (QoL) in patients with breakthrough cancer pain (BTcP) in Spanish medical oncology departments. Patients & methods: In a prospective, observational, multicenter study, we assessed QoL using the EQ-5D-5L instrument at baseline and after 15 and 30 days of individualized BTcP therapy, as well as BTcP characteristics and treatment. Results: Patients (n = 118) were mainly women, over 64 years old and with advanced cancer. QoL improved at 15 (p = 0.013) and 30 days (p = 0.011) versus baseline. Individualized BTcP therapy consisted mostly of rapid-onset opioids (transmucosal fentanyl at doses of 67-800 μg) according to the physician evaluation. BTcP improved, including statistically significant reductions in intensity, duration, number of episodes in the last 24 h and time to onset of BTcP relief. Conclusion: QoL increased after individualized pain therapy in patients with advanced cancer and BTcP in medical oncology departments. Keywords: breakthrough cancer pain; medical oncology; quality of life; rapid-onset opioids; transmucosal fentanyl.
dc.relation.ispartof	Future Oncology, 2022, vol. 18, num. 35, p. 3913-3927
dc.subject	Càncer Pacients
dc.subject	Tractament pal·liatiu
dc.title	Increased quality of life in patients with breakthrough cancer pain after individualized therapy : the CAVIDIOM study
dc.type	journal article
dc.date.updated	2023-04-18T16:24:19Z
dc.identifier.doi	10.2217/fon-2022-0758
dc.identifier.idgrec	157556
dc.rights.accessRights	open access